Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LivaNovaLIVN +0.51%78 EV-to-EBITDA is 19.53 as of Aug. 11, 2026, which is 36% above its 10-year median of 14.39. GuruFocus rates LIVN with a GF Score™ of 78/100 and a GF Value™ of $63.10 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, LivaNova ranks worse than 63.57% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LivaNova's enterprise value is $4,071 Mil.
LivaNova's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $208 Mil. Therefore, LivaNova's EV-to-EBITDA for today is 19.53.
The historical rank and industry rank for LivaNova's EV-to-EBITDA or its related term are showing as below:
LIVN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -791.28 Med: 14.39 Max: 343.21
Current: 19.53
During the past 13 years, the highest EV-to-EBITDA of LivaNova was 343.21. The lowest was -791.28. And the median was 14.39.
LIVN's EV-to-EBITDA is ranked worse than 63.57% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.81
vs LIVN: 19.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LivaNova's share price for today is $76.88.
LivaNova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for LivaNova's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LivaNova's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LivaNova's EV-to-EBITDA falls into.
LivaNova's current Enterprise Value is $4,071 Mil.
LivaNova's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $208 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova (LIVN) has a EV-to-EBITDA of 19.53 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LivaNova. This is 36% above median its historical median of 14.39. According to the industry distribution chart, LivaNova ranks #328 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 63.6%.
Is LivaNova's EV-to-EBITDA too high?
LivaNova's current EV-to-EBITDA of 19.53 is 36% above median its 10-year median of 14.39. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.81. LivaNova's value of 19.53 is 31.9% above this industry median. Based on the distribution chart, LivaNova ranks #328 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LivaNova has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's EV-to-EBITDA compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #328 out of 516 companies for EV-to-EBITDA. This places LivaNova in the lower half of its industry. The industry median EV-to-EBITDA is 14.81. LivaNova's value of 19.53 is 31.9% above this benchmark. While the company's 10-year median is 14.39 vs. the industry median of 14.81, LivaNova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.81, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LivaNova's current EV-to-EBITDA of 19.53 is 31.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LivaNova. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LivaNova's current EV-to-EBITDA is 19.53, which is 36% above median its own 10-year median of 14.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Modestly Overvalued. The stock's GF Value™ is $63.10, compared to a current price of $76.88 — trading 21.8% above its estimated fair value. The current EV-to-EBITDA is 19.53, which is 36% above median its 10-year median of 14.39 and 31.9% above the Medical Devices & Instruments industry median of 14.81. LivaNova's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LivaNova (LIVN), the current EV-to-EBITDA is 19.53 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (LIVN) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of $76.88 is trading 21.8% above its estimated GF Value™ of $63.10.
GuruFocus considers LivaNova to be Modestly Overvalued.
Key valuation signals for LIVN:
EV-to-EBITDA: 19.53 (36% above median its 10-year median of 14.39)
GF Value™: $63.10 vs. price of $76.88 (21.8% above fair value)
Industry Position: 31.9% above the Medical Devices & Instruments median (#328 of 516)
No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
78GF Score
Get the complete analysis for LIVN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIVN has been successfully added to your 
